Interferon-induced helicase (IFIH1) polymorphism with systemic lupus erythematosus and dermatomyositis/polymyositis

Modern Rheumatology

Volumn 20, Issue 5, 2010, Pages 466-470

  Gono, Takahisa ^a   Kawaguchi, Yasushi ^a   Sugiura, Tomoko ^a   Furuya, Takefumi ^a   Kawamoto, Manabu ^a   Hanaoka, Masanori ^a   Yamanaka, Hisashi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Dermatomyositis; IFIH1; Interstitial lung disease; Polymyositis; Systemic lupus erythematosus

Indexed keywords

INTERFERON INDUCED HELICASE; RETINOIC ACID INDUCIBLE PROTEIN I; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; INTERSTITIAL LUNG DISEASE; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; CASE-CONTROL STUDIES; DEAD-BOX RNA HELICASES; DERMATOMYOSITIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 78049344947     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-010-0311-9     Document Type: Article

References (16)

1. O Takeuchi S Akira 2008 MDA5/RIG-I and virus recognition Curr Opin Immunol 20 1 17 22 1:CAS:528:DC%2BD1cXisVWhu7g%3D 10.1016/j.coi.2008.01.002 18272355
2. M Yoneyama M Kikuchi K Matsumoto T Imaizumi M Miyagishi K Taira, et al. 2005 Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity J Immunol 175 5 2851 2858 1:CAS:528: DC%2BD2MXos1Gisb0%3D 16116171
3. L Rönnblom G Alm K Oberg 1991 Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment Acta Oncol 30 4 537 540 10.3109/02841869109092414 1854511
4. J Banchereau V Pascual 2006 Type I interferon in systemic lupus erythematosus and other autoimmune diseases Immunity 25 3 383 392 1:CAS:528:DC%2BD28XhtVOjtL%2FJ 10.1016/j.immuni.2006.08.010 16979570 (Pubitemid 44354221)
5. P Gerami J Schope L McDonald H Walling R Sontheimer 2006 A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies J Am Acad Dermatol 54 4 597 613 10.1016/j.jaad.2005.10. 041 16546580
6. S Sato M Hirakata M Kuwana A Suwa S Inada T Mimori, et al. 2005 Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis Arthritis Rheum 52 5 1571 1576 1:CAS:528:DC%2BD2MXkvFCisrc%3D 10.1002/art.21023 15880816 (Pubitemid 40663949)
7. S Sato K Hoshino T Satoh T Fujita Y Kawakami M Kuwana 2009 RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease Arthritis Rheum 60 7 2193 2200 1:CAS:528:DC%2BD1MXptlKrsbw%3D 10.1002/art.24621 19565506
8. M Christensen L Pachman R Schneiderman D Patel J Friedman 1986 Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis Arthritis Rheum 29 11 1365 1370 1:STN:280:DyaL2s%2FkvV2qtA%3D%3D 10.1002/art.1780291109 3022759 (Pubitemid 17214037)
9. D Smyth J Cooper R Bailey S Field O Burren L Smink, et al. 2006 A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region Nat Genet 38 6 617 619 1:CAS:528:DC%2BD28XltVOhur4%3D 10.1038/ng1800 16699517 (Pubitemid 43927300)
10. A Sutherland J Davies C Owen S Vaikkakara C Walker T Cheetham, et al. 2007 Genomic polymorphism at the interferon-induced helicase (IFIH1) locus contributes to Graves' disease susceptibility J Clin Endocrinol Metab 92 8 3338 3341 1:CAS:528:DC%2BD2sXptl2htb0%3D 10.1210/jc.2007-0173 17535987 (Pubitemid 47236412)
11. V Gateva J Sandling G Hom K Taylor S Chung X Sun, et al. 2009 A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus Nat Genet 41 11 1228 1233 1:CAS:528:DC%2BD1MXht1OgsrzN 10.1038/ng.468 19838195
12. E Tan A Cohen J Fries A Masi D McShane N Rothfield, et al. 1982 The 1982 revised criteria for the classification of systemic lupus erythematosus Arthritis Rheum 25 11 1271 1277 1:STN:280:DyaL3s%2FkvVCmtA%3D%3D 10.1002/art.1780251101 7138600 (Pubitemid 13221242)
13. A Bohan J Peter 1975 Polymyositis and dermatomyositis (first of two parts) N Engl J Med 292 7 344 347 1:STN:280:DyaE2M7hvVyrtA%3D%3D 10.1056/NEJM197502132920706 1090839
14. M Dalakas 1995 Immunopathogenesis of inflammatory myopathies Ann Neurol 37 Suppl 1 S74 S86 10.1002/ana.410370709 8968219
15. H Tokita H Fukui A Tanaka H Kamitsukasa M Yagura H Harada, et al. 2003 Circulating KL-6 level at baseline is a predictive indicator for the occurrence of interstitial pneumonia during interferon treatment for chronic hepatitis C Hepatol Res 26 2 91 97 1:CAS:528:DC%2BD3sXksVegtLk%3D 10.1016/S1386-6346(03) 00008-1 12809935 (Pubitemid 36927178)
16. T Okanoue S Sakamoto Y Itoh M Minami K Yasui M Sakamoto, et al. 1996 Side effects of high-dose interferon therapy for chronic hepatitis C J Hepatol 25 3 283 291 1:CAS:528:DyaK28Xmtleisrw%3D 10.1016/S0168-8278(96)80113-9 8895006 (Pubitemid 26323465)